Key Highlights

  • An executive with more than 25 years' experience has been appointed Head of Clinical Site Development & Expansion.
  • The appointment commences on 1 December 2026 and leads the TrialsWest east-coast network.
  • The role is funded by the recent placement, which referenced an East-Coast General Manager position.
  • The first east-coast sites are expected to open from H2 FY27, at a rate of about two a year.

Resonance Health Limited (ASX:RHT) has appointed an experienced clinical operations leader as Head of Clinical Site Development & Expansion, to lead the east-coast expansion of its TrialsWest clinical trial site network, in an announcement dated 4 November 2026. The appointment will formally commence on 1 December 2026.

Executive Background

The executive has more than 25 years' experience across the clinical trial ecosystem, including investigator sites, research governance and global pharmaceutical and biotechnology organisations. Most recently, the executive worked at a clinical-stage biotechnology company responsible for clinical research across Phase I to III studies.

The announcement sets out this background as the basis for the appointment.

The executive's background in investigator sites and research governance covers the operational areas that the expansion depends on. The release describes the previous role at a clinical-stage biotechnology company, where responsibilities covered Phase I to III studies, and sets that range of experience out as the basis for the appointment.

Expansion Timetable and Network

Site identification has begun in target geographies. The first east-coast sites are expected to open from the second half of FY27, at a rate of approximately two per year, according to the announcement.

The company says the east-coast network will draw on TrialsWest's more than 20 existing active trials and its established relationships with pharmaceutical and contract research sponsors.

The existing trials and sponsor relationships of the TrialsWest network are described as the foundation for the east-coast program. The approach applies existing capabilities to new geographies, with the rollout pace set at approximately two sites a year.

Link to the Placement

The role is funded by the recent placement. The release notes that the position was referenced as an East-Coast General Manager role in the Placement investor presentation released to the ASX on 27 October 2026.

The appointment is therefore presented as the operational step following that Capital raising, with site identification as the immediate task.

The placement investor presentation referred to the position as an East-Coast General Manager role, and the announcement now names it as Head of Clinical Site Development & Expansion. The release does not explain the change in title, and it describes the scope of responsibilities only in general terms.

Placement and Growth Plans

The announcement connects the new role with the recent placement, which referenced the East-Coast General Manager position. The company's growth plan for the east coast is staged, with site identification beginning now and the first sites expected in the second half of FY27. The release does not give Revenue or cost targets for the east-coast network, and it does not set out the funding allocated to the rollout beyond the appointment itself.

Final Word

The announcement records a senior appointment and a phased expansion timetable, but it does not include financial guidance or revenue figures. The pace of the rollout, at roughly two sites a year, is set out in the release, and progress will depend on identifying suitable sites within the target geographies.